Areas reviewed: Chemical studies dealing with the modification or development of drugs. Preclinical studies involving toxicity and effectiveness, and the development of drug delivery systems. Pharmacological studies, and studies involving nuclear magnetic resonance and crystallography, on the mechanisms of drug action, and the application of this information to drug design. Studies on the isolation, testing, and synthesis of natural therapeutic agents.

Demetrios Braddock, MD, PhD, Chair
Yale University
New Haven, CT

Coran Watanabe, PhD, Vice Chair
Texas A&M University
College Station, TX

Jing Chen, PhD
Emory University
Atlanta, GA

Adrienne Cox, PhD
University of North Carolina
Chapel Hill, NC

Laird Forrest, PhD
University of Kansas
Lawrence, KS

Sandaruwan Geeganage, PhD
Eli Lilly and Company
Indianapolis, IN

Curt Gill, Stakeholder
Ft. Wayne, IN

Balazs Halmos, MD
Columbia University
New York, NY

Eric Haura, MD
Moffitt Cancer Center
Tampa, FL

William Hawkins, MD
Washington University
St. Louis, MO

Seth Herzon, PhD
Yale University
New Haven, CT

Christine Hrycyna, PhD
Purdue University
West Lafayette, IND

Joseph Kissil, PhD
Scripps Research Institute
Jupiter, FL

Joerg Lahann, PhD
University of Michigan
Ann Arbor, MI

Robert Orlowski, MD, PhD
University of Texas/M.D. Anderson Cancer Center
Houston, TX

Keykavous Parang, PhD, PharmD
University of Rhode Island
Providence, RI

Rich Truett, Stakeholder
Eugene, OR

Susan Wee, PhD
Bristol-Myers Squibb Company
Princeton, NJ